PhRMA’s ‘Better Way:’ Remember COVID Success, Tweak Part B, And Bash HR 3

Trade group’s new agenda offers few original solutions to tackle US drug costs, relying on old standbys and reminders of what medical innovation might be lost if industry is financially targeted by policy makers with a strong nod to drug manufacturers role the current pandemic.

Rx pad. Shutterstock photo 268883147
The brand trade group hopes it has found the right prescription for the coming drug pricing fight. • Source: Shutterstock

The Pharmaceutical Researchers and Manufacturers of America new “Better Way” Agenda for the US health care system doesn’t offer much in the way of original policy ideas industry will bring to the drug pricing debate. Instead, manufacturers appear to largely be relying on a reputation boost by reminding the public and politicians of its role in developing drugs and vaccines for COVID-19 and warning not to take that for granted – that some new future medicines won’t ever come to fruition if the industry’s profits are cut.

The trade group’s new agenda, which plays off the name of the White House’s “Build Back Better” plan to address...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access